Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia

Niitsu, Tomihisa; Shirayama, Yukihiko; Matsuzawa, Daisuke; Hasegawa, Tadashi; Kanahara, Nobuhisa; Hashimoto, Tasuku; Shiraishi, Tetsuya; Shiina, Akihiro; Fukami, Goro; Fujisaki, Mihisa; Watanabe, Hiroyuki; Nakazato, Michiko; Asano, Makoto; Kimura, Sho; Hashimoto, Kenji; Iyo, Masaomi

doi:10.1016/j.pnpbp.2011.09.004

Cited by 59 publications

(42 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, BDNF levels were correlated with semantic generation, which is in line with literature findings relating BDNF to verbal working memory in healthy volunteers (Niitsu et al, 2011). Most studies evaluating BDNF and cognition in schizophrenia investigate the association between BDNF Val66Met polymorphism and domains of cognition (e.g.…”

Section: Discussionsupporting

confidence: 92%

“…Although several studies described reductions of BDNF levels in individuals with SZ when compared with a healthy control group (Favalli et al, 2012;Martinotti et al, 2012;Zhang et al, 2012), there are also reports of non-altered levels (Niitsu et al, 2011) or even increased BDNF levels with antipsychotic treatment (Noto et al, 2011;Reis et al, 2008;Yoshimura et al, 2012). Possible explanations for these differences are variations in medication use, especially in the proportion of the sample that was under clozapine use (Pedrini et al, 2012), and presence of psychiatric comorbidities (Noto et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Asevedo

Gadelha

Noto

et al. 2013

Journal of Psychiatric Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Asevedo

Gadelha

Noto

et al. 2013

Journal of Psychiatric Research

View full text Add to dashboard Cite

“…These activated microglia then release TNF-α and IL-6 [6] contributing to the diseased state of the brain in schizophrenia. The presence of an exaggerated immune response and downstream signalling of pro-inflammatory cytokines in MDD and schizophrenia are thought to be the underlying causes of the impairments in learning and memory, as well as increased anxiety and sleep disturbances [9,20] seen in these psychiatric illnesses. Indeed, neurodegeneration induced by this neuroinflammatory state is seen as a reduction in hippocampal volume in depressed patients [21], which is associated with mild to moderate impairments in cognitive performance compared to healthy norms.…”

mentioning

confidence: 99%

Tumour necrosis factor - alpha mediated mechanisms of cognitive dysfunction

Baune

Camara²,

Eyre³

et al. 2012

Translational Neuroscience

View full text Add to dashboard Cite

Background: Tumour necrosis factor -alpha (TNF-α) is a pro-inflammatory cytokine that combines a plethora of activities in the early stages of an immune response. TNF-α has gained increasing importance given TNF-α upregulation in multiple brain pathologies like neuropsychiatric conditions such as depression, schizophrenia, as well as neuroinflammatory disorder like multiple sclerosis (MS). Aim: The aim of this review is to critically analyse neurobiological, immunological and molecular mechanisms through which TNF-α influences the development of cognitive dysfunction. Principal findings/results: The review presents several lines of original research showing that the immunological properties of TNF-α exacerbate inflammatory responses in the central nervous system such as microglial and endothelial activation, lymphocytic and monocytic infiltration and the expression of downstream pro-inflammatory cytokines and apoptotic factors. Depression, schizophrenia, and MS all manifest symptoms of activated immune response along with cognitive dysfunction, with TNF-α overexpression as a central clinical feature common to these disorders. Furthermore, TNF-α acts negatively on neuroplasticity and the molecular mechanisms of memory and learning (i.e., long-term potentiation and long-term depression). TNF-α also exerts influence over the production of neurotrophins (i.e., nerve growth factor and brain-derived neurotrophic factor), neurogenesis, and dendritic branching. Conclusions/significance: This review outlines that TNF-α and its receptors have a substantial yet underappreciated influence on the development and progression of neuropsychiatric symptoms across several disease entities. An improved understanding of these underlying mechanisms may help develop novel therapeutic targets in the form of drugs specifically targeting downstream products of TNF-α activation within the central nervous system.

show abstract

“…In relation to schizophrenia, a study detected a significant positive correlation between serum BDNF levels and decreased cognitive functioning in 250 Chinese inpatients with schizophrenia [81] . In another study, serum truncated-BDNF abundance predicted a high presence of cognitive impairments, showing 67.5% of sensitivity and 97.5% of specificity [82] in the prediction. This result suggests that deficiency in pro-BDNF processing may be involved in the mechanism underlying the cognitive impairments observed in schizophrenia.…”

Section: Bdnf and Cognitionmentioning

confidence: 91%

Brain-derived neurotrophic factor as a potential biomarker of cognitive recovery in schizophrenia

Penadés

Catalán²,

López-Vílchez³

et al. 2013

WJP

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) has been proposed as a biomarker of schizophrenia and, more specifically, as a biomarker of cognitive recovery. Evidence collected in this review indicates that BDNF is relevant in the pathophysiology of schizophrenia and could play a role as a marker of clinical response. BDNF has been shown to play a positive role as a marker in antipsychotic treatment, and it has been demonstrated that typical antipsychotics decrease BDNF levels while atypical antipsychotics maintain or increase serum BDNF levels. Furthermore, BDNF levels have been associated with severe cognitive impairments in patients with schizophrenia. Consequently, BDNF has been proposed as a candidate target of strategies to aid the cognitive recovery process. There is some evidence suggesting that BDNF could be mediating neurobiological processes underlying cognitive recovery. Thus, serum BDNF levels seem to be involved in some synaptic plasticity and neurotransmission processes. Additionally, serum BDNF levels significantly increased in schizophrenia subjects after neuroplasticity-based cognitive training. If positive replications of those findings are published in the future then serum BDNF levels could be definitely postulated as a peripheral biomarker for the effects of intensive cognitive training or any sort of cognitive recovery in schizophrenia. All in all, the current consideration of BDNF as a biomarker of cognitive recovery in schizophrenia is promising but still premature.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Schizophrenia; Brain-derived neurotrophic factor; Cognition; Biomarkers Core tip: The lack of diagnostic and treatment markers is one of the most important problems in clinical practice. Brain-derived neurotrophic factor (BDNF) has been proposed as a biomarker of schizophrenia and, more specifically, as a biomarker of cognitive recovery. Evidence collected in this review indicates that there is evidence suggesting that serum BDNF levels are involved in some synaptic plasticity processes. Additionally, serum BDNF levels significantly increased in schizophrenia subjects after neuroplasticity-based cog-

show abstract

Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia

Cited by 59 publications

References 49 publications

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia

Tumour necrosis factor - alpha mediated mechanisms of cognitive dysfunction

Brain-derived neurotrophic factor as a potential biomarker of cognitive recovery in schizophrenia

Contact Info

Product

Resources

About